• Enveda, a biotech startup, has raised $55 million in a Series A funding round to develop a platform that combines ancient herbal remedies with AI-powered drug discovery. The company's approach aims to uncover new therapeutic compounds by analyzing the chemical composition and biological activity of traditional medicines from around the world.

• Enveda's platform leverages machine learning algorithms to analyze vast datasets of traditional herbal formulations, identifying promising compounds that could have therapeutic potential. By integrating this data with modern drug discovery techniques, the company hopes to accelerate the development of new drugs and treatments.

• The funding will be used by Enveda to expand its team, further develop its AI-driven drug discovery platform, and advance its pipeline of drug candidates. The company's co-founders, Mani Doraisamy and Sanjay Khuperkar, believe that their approach can uncover novel therapeutic solutions by tapping into the wealth of knowledge contained in traditional medicine systems.